Dissolution Behavior of Carbamazepine Suspensions Using the Usp Dissolution Apparatus 2 and the Flow-Through Cell Method With Simulated Gi Fluids

Abstract

Objective: To characterize the dissolution behaviour of carbamazepine generic suspensions using the USP Dissolution Apparatus 2 and the flow-through cell method with simulated gastrointestinal fluids as dissolution media.Methods: Tegretol® suspension and two generic formulations were tested. Dissolution studies were performed using the USP Apparatus 2 (75 rpm and 900 ml of dissolution medium) and the flow-through cell method (laminar flow at 16 ml/min). Simulated gastric fluid (SGF) (with and without pepsin) and simulated intestinal fluid (SIF) (without pancreatin) at 37.0±0.5 °C, was used as dissolution media. The quantity of dissolved carbamazepine was determined at 5 min intervals until reaching 60 min, at 285 nm. Percentage dissolved at 60 min, mean dissolution time, dissolution efficiency values (model-independent parameters), as well as t50% and t63.2% were calculated (model-dependent parameters). Values for all parameters were compared between the reference and generic formulations using one-way analysis of variance (ANOVA) following a Dunnett’s multiple comparison test. Dissolution data were also fitted to different fit models.Results: Since the first sampling time, the reference product had reached 100% of drug dissolved, which was determined using USP Apparatus 2. Nevertheless, significant differences in the three model-independent parameters of generic products were found (*P<0.05). Dissolution data obtained with the paddle apparatus were fitted to different kinetic equations; however, using the flow-through cell method and SIF without pancreatin, the three drug products were fitted to the same kinetic model (Gompertz). With ANOVA-based comparisons and the flow-through cell method, significant differences were found in dissolution data of generic product A versus reference at all sampling times (*P<0.05). The flow-through cell method and SGF with pepsin were the best options to discriminate among dissolution profiles.Conclusion: The flow-through cell method seems to be an adequate dissolution apparatus to characterize in vitrodissolution performance of Class II drugs manufactured as suspensions. For carbamazepine suspensions, SGF and laminar flow at 16 ml/min were the most appropriate conditions to discriminate among generic formulations. Given the physicochemical characteristics of carbamazepine and the environment in which the drug products were tested, these differences could be of clinical relevance.

Comparative in Vitro Dissolution Study on Metformin Market Products Using Different Dissolution Apparatuses

“…On the other hand, USP apparatus IV was more beneficial in the development of a much more discriminating dissolution method than the pharmacopeial method, similar observations were stated by Medina et al [46] who studied in vitro dissolution profiles of carbamazepine IR generic tablet products using different dissolution apparatuses (II and IV). In a recent study, similar observation regarding USP apparatus IV and II was noticed for marketed suspensions of carbamazepine [47]. Again this was in accordance with the work done by Gite et al [51] on atorvastatin using USP apparatus I and IV.…”

Formulation and Investigation of CK2 Inhibitor-Loaded Alginate Microbeads with Different Excipients

“…Samples were previously filtered through a 0.45 µm membrane filter and the amount of DMAT was determined using a standard calibration curve. The absorbance of the samples was measured at 420 nm using UV/VIS [ 34 ].…”

Dissolution Performance of Verapamil-HCl Tablets Using USP Apparatus 2 and 4: Prediction of In Vivo Plasma Profiles

“…The results of this comparative dissolution study for verapamil-HCl tablets agree with those reported by other authorsapparatus 4 was more accurate than USP Apparatus 2. Details of the successful association of MDT and modelparameters of naproxen tablets, ibuprofen suspensions, and fixed-dose combination formulations of acetaminophen and ibuprofen have been reported (27)(28)(29).…”